Competition & Markets Authority
Illumina/PacBio abandon merger
Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
The Competition and Markets Authority (CMA) has therefore today confirmed that it will be cancelling its Phase 2 merger investigation.
Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio) are both global suppliers of Next-Generation DNA sequencing systems to organisations across the world, including UK universities, laboratories and research institutes. DNA sequencing systems are vital to the study of genetic variation in humans and other species, for purposes such as essential disease research and drug development.
The CMA launched a Phase 2 inquiry in July 2019 after initial competition concerns led to the proposed merger being referred to a group of independent CMA panel members for an in-depth investigation.
The CMA provisionally found in October 2019 that the merger would result in a significant loss of competition between the 2 companies, with few alternative providers of DNA sequencing systems remaining. The CMA was also concerned that the loss of PacBio as an independent competitor would lead to a reduction in overall levels of innovation in the market. The CMA had proposed that blocking the merger would be the only way of addressing these concerns.
The deal was also being investigated by the US Federal Trade Commission, and the 2 authorities have cooperated closely throughout their respective investigations.
Illumina and PacBio have now decided not to continue with the deal. More information is available on the Illumina / PacBio case page.
Latest News from
Competition & Markets Authority
The UK’s withdrawal from the EU - The CMA’s role post Brexit29/01/2020 13:20:00
The Government has confirmed that the UK will enter a transition period until the end of December 2020, following its departure from the EU on 31 January 2020.
Second firm admits illegal role in agreement for essential drug24/01/2020 10:10:00
Drug company Tiofarma has admitted that it took part in an agreement that resulted in significant price hikes for an essential medicine.
CMA consults on annual plan24/01/2020 09:10:00
The CMA has launched a consultation on its annual plan for 2020/21
Guitar maker fined £4.5m for illegally preventing price discounts23/01/2020 09:20:00
The CMA has fined Fender Europe £4.5 million for breaking competition law by preventing online discounting for its guitars.
CMA publishes loyalty penalty update22/01/2020 12:20:00
The CMA has reported on the progress made in tackling the loyalty penalty that impacts millions of people.
Court of Appeal upholds CMA decision on online sales21/01/2020 14:43:00
The Court of Appeal has upheld the CMA’s finding that a golf equipment supplier acted illegally by banning online sales of its products.
Facebook and eBay pledge to combat trading in fake reviews09/01/2020 09:20:00
Following action from the CMA, Facebook and eBay have committed to combatting the trade of fake and misleading reviews on their sites.
LN-Gaiety’s purchase of MCD cleared by CMA20/12/2019 12:20:00
An in-depth CMA investigation has found that Live Nation-Gaiety’s proposed purchase of MCD does not raise competition concerns.